Holen Sie sich die Stockscreener-App
22.76
1.39%
-0.32
Handel nachbörslich:
22.70
-0.06
-0.26%
Schlusskurs vom Vortag:
$23.08
Offen:
$23.7
24-Stunden-Volumen:
657.79K
Relative Volume:
0.51
Marktkapitalisierung:
$2.58B
Einnahmen:
$4.02M
Nettoeinkommen (Verlust:
$-224.59M
KGV:
-9.565
EPS:
-2.3795
Netto-Cashflow:
$-205.52M
1W Leistung:
+2.48%
1M Leistung:
+7.41%
6M Leistung:
-7.55%
1J Leistung:
+116.35%
1-Tages-Spanne:
$22.48
$23.70
1-Wochen-Bereich:
$22.23
$23.78
52-Wochen-Spanne:
$8.665
$27.65
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
22.76 | 2.56B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-28 | Eingeleitet | Barclays | Overweight |
| 2026-02-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Truist | Buy |
| 2025-09-22 | Eingeleitet | Goldman | Buy |
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
IMNM|Immunome Inc|Price:22.590|Chg%:+0.380 - TradingKey
Immunome CTO Philip Tsai Awarded 38,250 RSUs and 76,500 Stock Options in July 2026 Equity Grant - Kalkine Media
Immunome Grants Chief Business Officer Kinney Over $1.3 Million in Stock Options and RSUs - Kalkine Media
Immunome Inc (IMNM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunome Inc (IMNM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunome Inc (IMNM) Institutional Confidence - TradingKey
Immunome Inc (IMNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunome, Inc. Revenue Breakdown – BOATS:IMNM - TradingView
IMNM|Immunome Inc|Price:22.220|Chg%:+0.210 - TradingKey
TradingKey - TradingKey
Immunome Inc. (IMNM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Immunome Inc (IMNM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Australia
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
IMNM Reiterates by Wedbush -- Price Target Maintained at $31 - GuruFocus
Immunome doses first patient in IM-3050 trial - grafa.com
Immunome doses first patient in IM-3050 cancer therapy trial By Investing.com - Investing.com South Africa
Immunome (IMNM) Begins Phase 1 Trial for IM-3050 in Advanced Sol - GuruFocus
Immunome doses first patient in IM-3050 cancer therapy trial - Investing.com
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire
Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Immunome (IMNM) NDA Acceptance Puts Valuation Back In Focus - Sahm
Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data - webull.com
Immunome stock up 32% in a month: Here's what you should know - MSN
What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout | AI
Immunome granted FDA review for tumor candidate - msn.com
Immunome Inc. (IMNM) Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Pre-Revenue Stage - dars.gov.et
What This Immunome Sale Means a Day Before a Big FDA Milestone - The Motley Fool
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS) - The Globe and Mail
Immunome Stock Up 32% in a Month: Here's What You Should Know - The Globe and Mail
Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Form 4 Immunome Inc For: 9 July - Investing.com India
Form 4 Immunome Inc For: 9 July By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock By Investing.com - Investing.com South Africa
Immunome CBO Horn Kinney sells $27,300 in stock - Investing.com
Truist Financial Maintains Immunome(IMNM.US) With Buy Rating - Moomoo
Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares - Stock Titan
H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com - Investing.com India
H.C. Wainwright reiterates Immunome stock rating on FDA filing - Investing.com
Barclays Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review - Benzinga
Immunome secures FDA review for cancer drug varegacestat - grafa.com
Immunome granted FDA review for tumor candidate (IMNM:NASDAQ) - Seeking Alpha
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat - Investing.com
FDA accepts Immunome NDA for desmoid tumor treatment varegacestat By Investing.com - Investing.com South Africa
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Horn Kinney | CHIEF BUSINESS OFFICER |
Jul 07 '26 |
Sale |
25.00 |
1,092 |
27,300 |
0 |
| Barchas Isaac | Director |
Jul 06 '26 |
Sale |
24.11 |
83,094 |
2,003,396 |
125,410 |
| Barchas Isaac | Director |
Jul 07 '26 |
Sale |
24.20 |
16,906 |
409,125 |
108,504 |
| Lechleider Robert | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
8.73 |
55,000 |
480,150 |
70,805 |
| Lechleider Robert | Chief Medical Officer |
Jul 02 '26 |
Sale |
22.62 |
55,000 |
1,244,331 |
15,805 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):